CorMedix  logo
CorMedix CRMD
$ 7.77 1.04%
report update icon

Quarterly report 2026-Q2
added 08-13-2026

CorMedix Financial Statements 2025-2006 | CRMD

Annual Financial Statements CorMedix

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006

Market Cap

456 K 373 K 174 M 137 M 159 M 250 M 162 M 167 M 25.9 M 64.2 M 55.8 M 66.5 M 32.6 M 11.1 M 4.34 M 155 M - - - -

Shares

72 K 58.9 K 50.9 M 40.3 M 37.7 M 28.6 M 24.2 M 17.8 M 11 M 7.59 M 6.27 M 4.29 M 2.76 M 2.28 M 2.28 M 11.4 M - - - -

Historical Prices

6.33 6.33 3.42 3.4 4.23 8.75 6.35 10.1 2.35 8.3 8.9 15.5 11.3 4.65 1.7 13.6 - - - -

Net Income

163 M -17.9 M -46.3 M -29.7 M -28.2 M -22 M -16.4 M -26.8 M -33 M -24.6 M -18.2 M -20.5 M -9.13 M -3.43 M -6.71 M -10.9 M -8.12 M -9 M -7.24 M -975 K

Revenue

312 M 43.5 M - 65.4 K 191 K 239 K 283 K 430 K 329 K 224 K 210 K 189 K 2 K - - - - - - -

Cost of Revenue

22.1 M 3.03 M - 3.73 K 149 K 205 K 373 K 397 K 115 K 367 K -319 K -446 K -202 K - - - - - - -

Gross Profit

276 M 40.3 M - 61.7 K 42 K 34.4 K -90 K 33 K 214 K -143 K -109 K -257 K -200 K - - - - - - -

Operating Income

150 M -22.4 M -49 M -30.6 M -29.4 M -27.2 M -21 M -26.9 M -32.9 M -24.8 M -16.7 M -8.9 M -4.92 M -3 M -7.21 M -8.51 M - - - -

Interest Expense

- 1.4 M 34.3 K 26.5 K 15.9 K 33.2 K 787 K 1.87 K 5.62 K 1.31 K 3.96 K 2.09 K 1.44 M 383 K - 3.09 M - - - -

EBITDA

151 M -22.2 M -48.9 M -30.5 M -29.4 M -27.1 M -20.9 M -26.8 M -32.9 M -24.7 M -16.6 M -8.89 M -4.91 M -3.04 M -7.23 M -8.49 M - - - -

Operating Expenses

126 M 62.6 M 49 M 30.7 M 29.5 M 27.3 M 20.9 M 26.9 M 33.1 M 24.6 M 16.5 M 8.65 M 4.72 M 3.04 M 7.25 M 8.51 M - - - -

General and Administrative Expenses

68.2 M 30 M 17.7 M 20 M 16.3 M -13.9 M 9.87 M 8.07 M 8.65 M 8.88 M 10.3 M 7.33 M 3.49 M 1.86 M 3.15 M 3.01 M - - - -

All numbers in USD currency

Quarterly Income Statement CorMedix

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

67.9 M 79.5 M - 75.9 M 67.9 M 65.2 M 64.4 M 58.8 M 57.6 M 57.5 M 54.9 M 56.6 M 45.4 M 44.1 M 42.8 M 41.2 M 39.8 M 38.2 M 38.1 M 38.1 M 38.1 M 36.3 M 33.6 M 29.6 M 26.1 M 26.1 M 25.7 M 24 M 23.8 M 23.1 M 21.8 M 18.8 M 16.5 M 15.1 M 71.4 M 60.3 M 52.6 M 40.6 M 40.4 K 39.1 M 36.4 M 36 M 35.4 K 34.6 K 31.6 M 23.9 K 22.5 M 22.1 M 22 M 19.3 M 16.6 M 14.4 M 13 M 11.6 M 11.4 M 11.4 M 11.4 M 11.4 M 11.4 M 11.4 M 11.4 M 11.4 M

Net Income

19.8 M 38.6 M - 109 M 19.8 M 20.6 M - -2.78 M -14.2 M -14.5 M - -9.74 M -11.3 M -10.6 M - -6.85 M -7.6 M -7.03 M - -8.57 M -4.63 M -7.22 M - -6.6 M -3.78 M -5.56 M - -5.26 M -696 K -5.17 M - -10.2 M -8.56 M -10.2 M - -9.96 M -5.15 M -7.6 M -6.4 K -9.13 M -4.89 M -4.12 M -3.87 K -4.69 K -4.14 K -5.5 K - -5.04 M 3.51 M -16.7 M - -2.5 M -1.95 M -1.25 M - -1.02 M -613 K -899 K - -2.6 M -2.48 M -1.98 M

Revenue

39.7 M 127 M - 104 M 39.7 M 39.1 M - 11.5 M 806 K - - - - - - 6.82 K 21.3 K 7.64 K - 38.1 K 8.19 K 88.3 K - 93 K 16.4 K 74.1 K - 59.5 K 35.3 K 164 K - 373 K 7.55 K 23.2 K - 61.1 K 136 K 39.6 K 121 44.5 K 16.5 K 41.4 K 23 36 120 31 - 52.4 K 39.7 K 12.2 K - - - - - - - - - - - -

Cost of Revenue

1.81 M 12 M - 7.57 M 1.86 M 1.6 M - 635 K 510 K 819 K - - - - - 1.47 K 332 1.53 K - 25.2 K 14.4 K 61.3 K - 79.9 K 19.2 K 48.5 K - 79 K 21.1 K 227 K - 312 K 33.7 K 28.6 K - 66.7 K 18.1 K 93.6 K -85 43.9 K 187 K 50.2 K -164 -35 -102 -17 - -36.7 K -54.5 K -81 K - - - - - - - - - - - -

Gross Profit

37.9 M 105 M - 93.1 M 37.9 M 37.5 M - 10.8 M 296 K -819 K - - - - - 5.35 K 20.9 K 6.11 K - 12.9 K -6.24 K 26.9 K - 13.1 K -2.74 K 25.5 K - -19.5 K 14.1 K -63.3 K - 60.1 K -26.1 K -5.36 K - -5.58 K 118 K -54 K 36 529 -171 K -8.8 K -141 1 18 14 - 15.8 K -14.8 K -68.8 K - - - - - - - - - - - -

Operating Income

19.5 M 63.7 M - 51.3 M 19.5 M 20.1 M - -3.29 M -15.3 M -16.7 M - -10.5 M -11.8 M -11 M - -6.96 M -8.24 M -7.03 M - -8.56 M -5.88 M -7.21 M - -6.6 M -8.92 M -5.61 M - -5.17 M -5.54 M -4.92 M - -10.2 M -8.57 M -10.2 M - -8.01 M -7.02 M -7.62 M -6.43 K -9.16 M -4.91 M -4.15 M -3.89 K -4.71 K -4.14 K -3.91 K - -1.86 M -1.89 M -8.9 M - -1.26 M -1.29 M -807 K - -991 K -614 K -900 K - -2.6 M -2.48 M -2.01 M

Interest Expense

- - - - - - - - 6.56 K - - 13.1 K 5.85 K 8.78 K - 8.78 K 3.58 K 5.38 K - 5.38 K 5.18 K 5.18 K - 7.8 K 13.8 K 6.28 K - 172 K 307 K 302 K - - - 1.87 K - 2.81 K - - - - 41 992 - 1.61 K 3.69 K 859 - 553 513 465 - 312 K 661 K 440 K - 26.1 K - - - - - 29.8 K

EBITDA

19.5 M 74.2 M - 54.9 M - 20.2 M - - - -16.7 M - - - -11 M - -6.9 M -8.2 M -7.01 M - -8.52 M -5.86 M -7.2 M - -6.56 M -8.88 M -5.59 M - -5.11 M -5.5 M -4.9 M - -10.2 M -8.53 M -10.2 M - -7.99 M -7 M -7.61 M -6.43 K -9.14 M -4.9 M -4.14 M -3.89 K 6.38 K 2.98 K -756 - -1.85 M -1.89 M -8.9 M - -1.25 M -1.29 M -806 K - -986 K -610 K -898 K - -2.59 M -2.47 M -2.01 M

Operating Expenses

18.3 M 41.5 M - 41.7 M 18.3 M 17.4 M - 14.1 M 15.6 M 15.9 M - 10.5 M 11.8 M 11 M - 6.97 M 8.26 M 7.04 M - 8.58 M 5.88 M 7.24 M - 6.62 M 8.92 M 5.64 M - 5.15 M 5.55 M 4.86 M - 10.3 M 8.55 M 10.2 M - 8.01 M 7.14 M 7.56 M - 9.16 M 4.74 M 4.14 M - 4.71 M 4.15 M 3.93 M - 1.88 M 1.87 M 2.87 M - 1.26 M 1.29 M 807 K - 991 K 614 K 900 K - 2.6 M 2.48 M 2.01 M

General and Administrative Expenses

9.5 M 21.7 M - 25.5 M 9.5 M 9.69 M - 6.58 M 7.56 M 8.71 M - 3.74 M 3.75 M 7.61 M - 4.63 M 5.05 M 4.75 M - 3.84 M 3.36 M 4.6 M - 3.69 M 3.23 M 3.17 M - 2.63 M 2.57 M 1.98 M - 2.01 M 1.95 M 1.9 M - 1.99 M 2.05 M 2.64 M 2.43 K 2.32 K 1.97 K 2.16 K 2.27 K 2.95 K 2.36 K 2.69 K - 1.59 M 1.7 M 2.51 M - 505 K 909 K 552 K - 747 K 377 K 536 K - 877 K 898 K 834 K

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements CorMedix CRMD
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting CorMedix plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AnaptysBio AnaptysBio
ANAB
$ 51.7 1.83 % $ 1.5 B usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.73 3.61 % $ 258 M britainBritain
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.89 0.53 % $ 107 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Rezolute Rezolute
RZLT
$ 3.94 1.87 % $ 299 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.52 1.17 % $ 6.21 B israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 61.35 0.06 % $ 11.8 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 9.64 0.46 % $ 449 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 99.26 0.81 % $ 24 B germanyGermany
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Genocea Biosciences Genocea Biosciences
GNCA
- -15.0 % $ 3.04 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 3.63 3.93 % $ 795 M britainBritain
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
G1 Therapeutics G1 Therapeutics
GTHX
- - $ 370 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.17 0.46 % $ 3.57 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 14.24 0.35 % $ 1.27 B usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.03 0.3 % $ 251 M usaUSA
Codexis Codexis
CDXS
$ 1.37 1.45 % $ 119 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.61 0.38 % $ 497 M usaUSA
AbbVie AbbVie
ABBV
$ 265.12 0.09 % $ 469 B usaUSA
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.17 1.48 % $ 137 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.65 2.76 % $ 3.78 B canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.43 2.65 % $ 288 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.48 1.16 % $ 2.09 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.12 1.98 % $ 50.3 M israelIsrael
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 2.08 0.48 % $ 5.43 M usaUSA
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Kinnate Biopharma Kinnate Biopharma
KNTE
- - $ 123 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.15 1.67 % $ 13 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 22.64 0.85 % $ 717 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 118.51 4.93 % $ 12.3 B usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 7.45 0.19 % $ 99.2 M usaUSA
Curis Curis
CRIS
$ 0.88 0.85 % $ 11.6 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 55.7 0.23 % $ 5.01 B schweizSchweiz
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 11.8 8.21 % $ 932 M usaUSA
Champions Oncology Champions Oncology
CSBR
$ 4.95 0.38 % $ 68.5 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.88 0.62 % $ 935 M canadaCanada
Cue Biopharma Cue Biopharma
CUE
$ 32.85 3.6 % $ 3.11 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.72 2.38 % $ 13.8 M usaUSA